Comparison of short-term effects of atorvastatin or rosuvastatin combined with clopidogrel in coronary stenting patients with non-ST segment elevation acute coronary syndrome

Objective To Compare the short-term effects of atorvastatin or rosuvastatin combined with clopidogrel in coronary stenting patients with non-ST segment elevation acute coronary syndrome(NSTE-ACS). Methods One hundred and fifty-four coronary stenting patients with NSTE-ACS were randomly divided into atorvastatin group(n=74) or rosuvastatin group(n=80).Aspirin 100 mg and clopidogrel 75 mg once daily were administrated for at least 5 days,or aspirin 300 mg and clopidogrel 300 mg loading dose 12 hours before percutaneous coronary intervention(PCI).Adenosine diphosphate(ADP)(10 μmol/L) induced platelet aggregation ratio(PAR) was measured before aspirin and clopidogrel use,the day of PCI,and 3 d,7 d,and one month after PCI.The main adverse cardiac events(MACE) in hospital and 6 months after PCI were evaluated. Results Baseline data between two groups were similar.Both groups achieved significant platelet inhibition [PAR from(57.2±10.3)% at baseline to(32.5±11.2)% the day of PCI and from(59.1±9.8)% to(30.4±10.1)% in rosuvastatin group,both P0.01] and last for six month after PCI.MACE rate had no difference between two groups(13.0% in atorvastatin group vs.15.0% in rosuvastatin group,P0.05). Conclusions Both atorvastatin and rosuvastatin have no significant influence on platelet inhibition effect of clopidogrel.The short-term effects of atorvastatin or rosuvastatin combined with clopidogrel in coronary stenting patients with NSTE-ACS are similar.